Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials
about
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinomaClaudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patientsPlatinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.Optimal chemotherapy treatment for women with recurrent ovarian cancerPhase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialTrabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.Second-line and subsequent therapy for ovarian carcinoma.Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicinInhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Current therapies in ovarian cancer.Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.Appropriate chemotherapy for palliating advanced cancerPrognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution StudyHow should we manage patients with "platinum-sensitive" recurrent ovarian cancer?Phase II trial of trimelamol in refractory ovarian cancerA phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.Platinum-Taxol non-cross resistance in epithelial ovarian cancerPaclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.Management of recurrent epithelial ovarian carcinoma.Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective StudyIndividuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancerTreatment decisions in advanced ovarian cancer.Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy.A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.Future directions in the management of epithelial ovarian cancer.Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.Oral melphalan as a treatment for platinum-resistant ovarian cancer.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer.Chemotherapy for gynecologic cancers.New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer.Timing for starting second-line therapy in recurrent ovarian cancer.Recurrent ovarian cancer: when and how to treat.Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
P2860
Q24791107-18724F98-9CA1-4C9E-9FC6-B4559AD95CA5Q30491616-AED68FD0-2990-4463-B1E0-AA43B0D65BA2Q30612061-E6723451-0771-40F2-9461-E6BBF2CD30CBQ30689000-E490C4E7-1059-4475-9B35-F5920FA71A9DQ33302771-F79F3B82-C1DB-4AF9-830F-C124120CF005Q33489855-B72ED89B-CB0B-4DDE-AD43-D5A661966588Q34413664-B270D4D9-503B-4235-AEB8-3E91E6DD7BF4Q34413670-AFE30D12-ED29-4039-B93F-FF1A82E6B00BQ34514120-D140A8DD-CE2E-4372-8BFC-B2E7078A9107Q34724590-4A00FAD5-E66B-4378-9BC3-AB04B3885785Q34811103-269A8C34-3DBF-4DA6-AA5B-D5EC8CF65213Q35087337-D688FCB7-55A7-4F5A-BCDD-BB0DD639012AQ35101318-355234E3-4D08-4E40-9846-8A8AE5D0B302Q35309283-D7F8E6B7-5E20-41E6-9062-024AEFDD910AQ35527133-994A184A-BCE1-4FDB-BBC7-A0A284FED4C3Q35591666-4B05D7F2-B655-4497-9C58-17BC33A19EC5Q35798931-2BAB6A74-E0A4-430F-ADFC-8D5D07C93A26Q35968737-E559F2B9-7404-42C7-AF08-B48123712965Q35983027-BC7325FD-25B5-45FE-8857-B1157C84FB39Q35993536-99CD3C55-7C51-4534-A384-A32F1ADD8877Q36080971-F7A53F5E-C52F-4B4B-8250-75B988D70256Q36081574-D5D5BFF6-AB52-4052-9CDC-BD433DF20770Q36200382-D08496ED-235D-456C-B8A1-C48474CF019FQ36229421-3B42BF05-5923-4A04-892E-535D3F7DEDE8Q36387788-3DD6CC5C-9CE3-4264-9D8E-95C529B8C878Q36467240-0B4279FD-5C39-4220-9AB3-BC52AFACD711Q36611274-363560A4-4770-4982-9C09-739C61F9D5A9Q36671560-DA7C2BC3-7CF0-4901-A9CF-D987917EC4E3Q37179400-1C3DA9D0-22B9-45BA-B98C-589F86860CE1Q37301481-EE052782-859C-4805-951E-6461980B1D14Q37340553-DA433D2F-49CE-4E3B-BE77-E15718F9A1D9Q37383301-ED893E1A-443A-4135-ABB1-1C3BD78F1402Q37567848-A868C100-F441-47CD-A974-26E4B873FC94Q37656085-5215FAD0-B252-4F9F-A793-A2163805CA02Q37809986-58641230-BD40-4381-815D-2C18ABEB91E2Q37821896-A28FE681-F9C3-4DF2-BFF2-A799632B20C3Q37951860-0353E7AA-1782-43A0-920A-DC6F8278AE49Q38205273-54DD3A14-A250-45A1-A3AD-5C96FFF3BDA3Q39400141-0F0F4505-FA4E-45F5-8D7C-714C9EE97B67Q40818758-49A20C1B-CFA4-4E2F-843A-6350E15F88DD
P2860
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Response of patients in phase ...... the design of phase II trials
@ast
Response of patients in phase ...... the design of phase II trials
@en
type
label
Response of patients in phase ...... the design of phase II trials
@ast
Response of patients in phase ...... the design of phase II trials
@en
prefLabel
Response of patients in phase ...... the design of phase II trials
@ast
Response of patients in phase ...... the design of phase II trials
@en
P2093
P921
P356
P1476
Response of patients in phase ...... the design of phase II trials
@en
P2093
P2888
P304
P356
10.1038/BJC.1989.132
P407
P577
1989-04-01T00:00:00Z